Rosemary Sutton

List of Publications by Year
in descending order

132 papers	6,407 citations	101543 36 h-index	71685 76 g-index
132 all docs	132 docs citations	132 times ranked	8102 citing authors

#	Article	IF	Citations
1	Methotrexate-related central neurotoxicity: clinical characteristics, risk factors and genome-wide association study in children treated for acute lymphoblastic leukemia. Haematologica, 2022, 107, 635-643.	3.5	16
2	Whole-genome sequencing facilitates patient-specific quantitative PCR-based minimal residual disease monitoring in acute lymphoblastic leukaemia, neuroblastoma and Ewing sarcoma. British Journal of Cancer, 2022, 126, 482-491.	6.4	7
3	Clonal dynamics in pediatric Bâ€cell precursor acute lymphoblastic leukemia with very early relapse. Pediatric Blood and Cancer, 2022, 69, e29361.	1.5	9
4	Correlation between a 10â€color flow cytometric measurable residual disease (<scp>MRD</scp>) analysis and molecular <scp>MRD</scp> in adult <scp>Bâ€acute</scp> lymphoblastic leukemia. Cytometry Part B - Clinical Cytometry, 2022, 102, 115-122.	1.5	4
5	Two novel cases of <i>NUTM1</i>â€rearranged Bâ€cell acute lymphoblastic leukaemia presenting with highâ€risk features. British Journal of Haematology, 2022, 196, 1407-1411.	2.5	4
6	Sensitive Measurement of Minimal Residual Disease in Blood by High Annealing TemperatureÂPCR. Journal of Molecular Diagnostics, 2022, , .	2.8	1
7	Measurable residual disease analysis in paediatric acute lymphoblastic leukaemia patients with ABL-class fusions. British Journal of Cancer, 2022, 127, 908-915.	6.4	2
8	Outcomes of paediatric patients with B-cell acute lymphocytic leukaemia with ABL-class fusion in the pre-tyrosine-kinase inhibitor era: a multicentre, retrospective, cohort study. Lancet Haematology,the, 2021, 8, e55-e66.	4.6	32
9	Outcomes for Australian children with relapsed/refractory acute lymphoblastic leukaemia treated with blinatumomab. Pediatric Blood and Cancer, 2021, 68, e28922.	1.5	16
10	CKLF and IL1B transcript levels at diagnosis are predictive of relapse in children with preâ€Bâ€cell acute lymphoblastic leukaemia. British Journal of Haematology, 2021, 193, 171-175.	2.5	2
11	Exploiting the reactive oxygen species imbalance in high-risk paediatric acute lymphoblastic leukaemia through auranofin. British Journal of Cancer, 2021, 125, 55-64.	6.4	16
12	Risk factors and outcomes in children with high-risk B-cell precursor and T-cell relapsed acute lymphoblastic leukaemia: combined analysis of ALLR3 and ALL-REZ BFM 2002 clinical trials. European Journal of Cancer, 2021, 151, 175-189.	2.8	27
13	Favorable outcome of NUTM1-rearranged infant and pediatric B cell precursor acute lymphoblastic leukemia in a collaborative international study. Leukemia, 2021, 35, 2978-2982.	7.2	40
14	Analytical Quality Controls for ddPCR Detection of Minimal Residual Disease in Acute Lymphoblastic Leukemia. Clinical Chemistry, 2021, 67, 1373-1383.	3.2	0
15	Minimal residual disease, long-term outcome, and IKZF1 deletions in children and adolescents with Down syndrome and acute lymphocytic leukaemia: a matched cohort study. Lancet Haematology,the, 2021, 8, e700-e710.	4.6	10
16	An MRD-stratified pediatric protocol is as deliverable in adolescents and young adults as in children with ALL. Blood Advances, 2021, 5, 5574-5583.	5.2	6
17	Relapses and treatment-related events contributed equally to poor prognosis in children with ABL-class fusion positive B-cell acute lymphoblastic leukemia treated according to AIEOP-BFM protocols. Haematologica, 2020, 105, 1887-1894.	3.5	33
18	Potent antileukemic activity of curaxin CBL0137 against MLLâ€rearranged leukemia. International Journal of Cancer, 2020, 146, 1902-1916.	5.1	30

#	Article	IF	Citations
19	Optimization of a clofarabineâ€based drug combination regimen for the preclinical evaluation of pediatric acute lymphoblastic leukemia. Pediatric Blood and Cancer, 2020, 67, e28133.	1.5	2
20	Addition of Thiotepa to Total Body Irradiation and Cyclophosphamide Conditioning for Allogeneic Hematopoietic Stem Cell Transplantation in Pediatric Acute Lymphoblastic Leukemia. Biology of Blood and Marrow Transplantation, 2020, 26, 2068-2074.	2.0	2
21	Highâ€risk Bâ€cell acute lymphoblastic leukaemia presenting with hypereosinophilia and acquiring a novel <i>PAX5</i> fusion on relapse. British Journal of Haematology, 2020, 191, 301-304.	2.5	3
22	Examining treatment responses of diagnostic marrow in murine xenografts to predict relapse in children with acute lymphoblastic leukaemia. British Journal of Cancer, 2020, 123, 742-751.	6.4	1
23	Enrichment of atypical hyperdiploidy and IKZF1 deletions detected by SNP-microarray in high-risk Australian AIEOP-BFM B-cell acute lymphoblastic leukaemia cohort. Cancer Genetics, 2020, 242, 8-14.	0.4	6
24	The application of RNA sequencing for the diagnosis and genomic classification of pediatric acute lymphoblastic leukemia. Blood Advances, 2020, 4, 930-942.	5.2	52
25	Genome-Wide Association Meta-Analysis of Single-Nucleotide Polymorphisms and Symptomatic Venous Thromboembolism during Therapy for Acute Lymphoblastic Leukemia and Lymphoma in Caucasian Children. Cancers, 2020, 12, 1285.	3.7	5
26	Genetic characterization and therapeutic targeting of <i>MYC</i>â€rearranged T cell acute lymphoblastic leukaemia. British Journal of Haematology, 2019, 185, 169-174.	2.5	9
27	Risk factors for symptomatic venous thromboembolism during therapy for childhood acute lymphoblastic leukemia. Thrombosis Research, 2019, 178, 132-138.	1.7	16
28	Human MLL/KMT2A gene exhibits a second breakpoint cluster region for recurrent MLLâ€“USP2 fusions. Leukemia, 2019, 33, 2306-2340.	7.2	41
29	IKZF1 Deletions with COBL Breakpoints Are Not Driven by RAG-Mediated Recombination Events in Acute Lymphoblastic Leukemia. Translational Oncology, 2019, 12, 726-732.	3.7	7
30	Outcomes of patients with childhood B-cell precursor acute lymphoblastic leukaemia with late bone marrow relapses: long-term follow-up of the ALLR3 open-label randomised trial. Lancet Haematology,the, 2019, 6, e204-e216.	4.6	36
31	Validation of the United Kingdom copy-number alteration classifier in 3239 children with B-cell precursor ALL. Blood Advances, 2019, 3, 148-157.	5.2	48
32	Germline deletion of ETV6 in familial acute lymphoblastic leukemia. Blood Advances, 2019, 3, 1039-1046.	5.2	21
33	More precisely defining risk peri-HCT in pediatric ALL: pre- vs post-MRD measures, serial positivity, and risk modeling. Blood Advances, 2019, 3, 3393-3405.	5.2	81
34	Age matters in <scp>ALL</scp>. British Journal of Haematology, 2018, 181, 429-430.	2.5	0
35	Pre-B acute lymphoblastic leukaemia recurrent fusion, EP300-ZNF384, is associated with a distinct gene expression. British Journal of Cancer, 2018, 118, 1000-1004.	6.4	28
36	The MLL recombinome of acute leukemias in 2017. Leukemia, 2018, 32, 273-284.	7.2	527

#	Article	IF	Citations
37	A risk score including microdeletions improves relapse prediction for standard and medium risk precursor Bâ€cell acute lymphoblastic leukaemia in children. British Journal of Haematology, 2018, 180, 550-562.	2.5	28
38	Targeted Next-Generation Sequencing for Detecting <i>MLL</i> Gene Fusions in Leukemia. Molecular Cancer Research, 2018, 16, 279-285.	3.4	27
39	Use of Thiotepa in Haematopoietic Stem Cell Transplantation for Paediatric Acute Lymphoblastic Leukaemia: An Australian and New Zealand Children's Haematology/Oncology Group Study. Biology of Blood and Marrow Transplantation, 2018, 24, S310.	2.0	0
40	High-Annealing-Temperature PCR (HAT-PCR) Enables Sensitive Quantification of Minimal Residual Disease (MRD) in Blood in Acute Lymphoblastic Leukaemia (ALL). Blood, 2018, 132, 2831-2831.	1.4	2
41	MLL-USP2: An Underestimated New Entity of MLL-Rearranged Leukemia Identified By NGS Analysis. Blood, 2018, 132, 3920-3920.	1.4	2
42	Quantitative Analysis of MLL Fusion Transcripts By Droplet Digital PCR to Monitor Minimal Residual Disease in MLL-Rearranged Acute Myeloid Leukemia. Blood, 2018, 132, 2746-2746.	1.4	0
43	Monitoring of childhood ALL using BCR-ABL1 genomic breakpoints identifies a subgroup with CML-like biology. Blood, 2017, 129, 2771-2781.	1.4	84
44	Tumor suppressors BTG1 and IKZF1 cooperate during mouse leukemia development and increase relapse risk in B-cell precursor acute lymphoblastic leukemia patients. Haematologica, 2017, 102, 541-551.	3.5	49
45	High prevalence of relapse in children with Philadelphia-like acute lymphoblastic leukemia despite risk-adapted treatment. Haematologica, 2017, 102, e490-e493.	3.5	52
46	Differential expression of MUC4, GPR110 and IL2RA defines two groups of CRLF2-rearranged acute lymphoblastic leukemia patients with distinct secondary lesions. Cancer Letters, 2017, 408, 92-101.	7.2	23
47	A novel somatic JAK2 kinase-domain mutation in pediatric acute lymphoblastic leukemia with rapid on-treatment development of LOH. Cancer Genetics, 2017, 216-217, 86-90.	0.4	10
48	Intragenic amplification of PAX5: a novel subgroup in B-cell precursor acute lymphoblastic leukemia?. Blood Advances, 2017, 1, 1473-1477.	5.2	25
49	Xenograft-directed personalized therapy for a patient with post-transplant relapse of ALL. Bone Marrow Transplantation, 2016, 51, 1279-1282.	2.4	5
50	Integration of genetic and clinical risk factors improves prognostication in relapsed childhood B-cell precursor acute lymphoblastic leukemia. Blood, 2016, 128, 911-922.	1.4	103
51	Acute Sensitivity of Ph-like Acute Lymphoblastic Leukemia to the SMAC-Mimetic Birinapant. Cancer Research, 2016, 76, 4579-4591.	0.9	20
52	Quantitative Phosphotyrosine Profiling of Patient-Derived Xenografts Identifies Therapeutic Targets in Pediatric Leukemia. Cancer Research, 2016, 76, 2766-2777.	0.9	16
53	Prognostic value of rare IKZF1 deletion in childhood B-cell precursor acute lymphoblastic leukemia: an international collaborative study. Leukemia, 2016, 30, 32-38.	7.2	81
54	Clinical Predictors of Venous Thromboembolism during Therapy for Childhood Acute Lymphoblastic Leukemia. Blood, 2016, 128, 1182-1182.	1.4	2

#	Article	IF	Citations
55	Comparison of MRD Levels and Gene Expression Patterns in MLL-R Versus Non-MLL Infant ALL. Blood, 2016, 128, 1740-1740.	1.4	1
56	<i>COBL</i> is a novel hotspot for <i>IKZF1</i> deletions in childhood acute lymphoblastic leukemia. Oncotarget, 2016, 7, 53064-53073.	1.8	9
57	A single nucleotide polymorphism genotyping platform for the authentication of patient derived xenografts. Oncotarget, 2016, 7, 60475-60490.	1.8	24
58	Heterogeneity in mechanisms of emergent resistance in pediatric T-cell acute lymphoblastic leukemia. Oncotarget, 2016, 7, 58728-58742.	1.8	18
59	Abstract B21: Genetic characterization and therapeutic targeting of MYC translocated pediatric T-cell acute lymphoblastic leukemia. Cancer Research, 2016, 76, B21-B21.	0.9	0
60	Identification of Multiple, Patient-Specific MLL Fusion Transcript Isoforms in Childhood Leukemia Using Anchored Multiplex PCR-Based Enrichment (AMP-E). Blood, 2016, 128, 2908-2908.	1.4	0
61	Induction of stem cell features in all cells by microenvironmental factors. Experimental Hematology, 2015, 43, S53.	0.4	0
62	AKR1C3 is a biomarker of sensitivity to PR-104 in preclinical models of T-cell acute lymphoblastic leukemia. Blood, 2015, 126, 1193-1202.	1.4	50
63	Bone Marrow Recovery by Morphometry during Induction Chemotherapy for Acute Lymphoblastic Leukemia in Children. PLoS ONE, 2015, 10, e0126233.	2.5	17
64	Effective Targeting of the P53â€"MDM2 Axis in Preclinical Models of Infant <i>MLL</i>-Rearranged Acute Lymphoblastic Leukemia. Clinical Cancer Research, 2015, 21, 1395-1405.	7.0	43
65	The landscape of somatic mutations in infant MLL-rearranged acute lymphoblastic leukemias. Nature Genetics, 2015, 47, 330-337.	21.4	405
66	Cerebral Vasculitis in X-linked Lymphoproliferative Disease Cured by Matched Unrelated Cord Blood Transplant. Journal of Clinical Immunology, 2015, 35, 604-609.	3.8	17
67	Persistent <scp>MRD</scp> before and after allogeneic <scp>BMT</scp> predicts relapse in children with acute lymphoblastic leukaemia. British Journal of Haematology, 2015, 168, 395-404.	2.5	66
68	Post Induction Minimal Residual Disease Levels Identifies a Group of High Risk Relapsed Childhood Acute Lymphoblastic Leukemia (rALL) with a Favorable Outcome Independent of Induction Therapy. Blood, 2015, 126, 1294-1294.	1.4	6
69	High Prevalence of Relapse in Australian Children with Ph-like Acute Lymphoblastic Leukemia Despite Risk Adapted Treatment. Blood, 2015, 126, 1419-1419.	1.4	1
70	Down syndrome and leukemia: insights into leukemogenesis and translational targets. Translational Pediatrics, 2015, 4, 76-92.	1.2	60
71	MRD Monitoring Using Minor-BCR-ABL1 Genomic Breakpoint in Childhood ALL Identifies a Subgroup with Distinct Biology and a Very Poor Prognosis. Blood, 2015, 126, 3727-3727.	1.4	0
72	Evaluation of Patient-Derived Xenografts for Modeling Outcome of Pediatric B-Cell Precursor Acute Lymphoblastic Leukemia. Blood, 2015, 126, 3759-3759.	1.4	0

#	Article	IF	Citations
73	A pre-clinical model of resistance to induction therapy in pediatric acute lymphoblastic leukemia. Blood Cancer Journal, 2014, 4, e232-e232.	6.2	28
74	Prognostic Value of Rare IKZF1 deletions in Childhood B-Cell Precursor Acute Lymphoblastic Leukemia: An International Collaborative Study. Blood, 2014, 124, 368-368.	1.4	3
75	Outcome of Central Nervous System Relapses In Childhood Acute Lymphoblastic Leukaemia â€“ Prospective Open Cohort Analyses of the ALLR3 Trial. PLoS ONE, 2014, 9, e108107.	2.5	34
76	High-risk childhood acute lymphoblastic leukemia in first remission treated with novel intensive chemotherapy and allogeneic transplantation. Leukemia, 2013, 27, 1497-1503.	7.2	54
77	A recurrent germline PAX5 mutation confers susceptibility to pre-B cell acute lymphoblastic leukemia. Nature Genetics, 2013, 45, 1226-1231.	21.4	270
78	The MLL recombinome of acute leukemias in 2013. Leukemia, 2013, 27, 2165-2176.	7.2	393
79	FBXW7 regulates glucocorticoid response in T-cell acute lymphoblastic leukaemia by targeting the glucocorticoid receptor for degradation. Leukemia, 2013, 27, 1053-1062.	7.2	38
80	Improving the Identification of High Risk Precursor B Acute Lymphoblastic Leukemia Patients with Earlier Quantification of Minimal Residual Disease. PLoS ONE, 2013, 8, e76455.	2.5	17
81	The Clinical Relevance Of Genetics In Predicting Outcome After a First Relapse In Children With B-Cell Precursor Acute Lymphoblastic Leukaemia. Blood, 2013, 122, 2566-2566.	1.4	1
82	Highly sensitive MRD tests for ALL based on the IKZF1 Î”3â€“6 microdeletion. Leukemia, 2012, 26, 1414-1416.	7.2	30
83	Differential diagnosis of paediatric bone pain: Acute lymphoblastic leukemia. Leukemia Research, 2012, 36, 521-523.	0.8	5
84	Abstract 4869: Whole genome sequence analysis of MLL rearranged infant acute lymphoblastic leukemias reveals remarkably few somatic mutations: A Report From the St Jude Children's Research Hospital - Washington University Pediatric Cancer Genome Project. , 2012, , .		4
85	Late Recurrence of Childhood T-Cell Acute Lymphoblastic Leukemia Frequently Represents a Second Leukemia Rather Than a Relapse: First Evidence for Genetic Predisposition. Journal of Clinical Oncology, 2011, 29, 1643-1649.	1.6	62
86	Whole Genome Sequence Analysis of 22 MLL Rearranged Infant Acute Lymphoblastic Leukemias Reveals Remarkably Few Somatic Mutations: A Report From the St Jude Childrenâ€˜s Research Hospital - Washington University Pediatric Cancer Genome Project. Blood, 2011, 118, 69-69.	1.4	6
87	Bone marrow fibrosis and vascular density lack prognostic significance in childhood acute lymphoblastic leukaemia. Leukemia, 2010, 24, 1537-1538.	7.2	7
88	Isolated testicular relapse after allo-SCT in boys with ALL: outcome without second transplant. Bone Marrow Transplantation, 2010, 45, 397-399.	2.4	3
89	Effect of mitoxantrone on outcome of children with first relapse of acute lymphoblastic leukaemia (ALL R3): an open-label randomised trial. Lancet, The, 2010, 376, 2009-2017.	13.7	282
90	Mitoxantrone Improves the Outcome of Children with Central Nervous System (CNS) Involvement at First Relapse of Acute Lymphoblastic Leukemia (ALL)-Results of the International ALLR3 Study. Blood, 2010, 116, 3303-3303.	1.4	0

#	Article	IF	Citations
91	Quantification of free total plasma DNA and minimal residual disease detection in the plasma of children with acute lymphoblastic leukemia. Annals of Hematology, 2009, 88, 897-905.	1.8	31
92	Clinical significance of minimal residual disease at day 15 and at the end of therapy in childhood acute lymphoblastic leukaemia. British Journal of Haematology, 2009, 146, 292-299.	2.5	56
93	New insights to the MLL recombinome of acute leukemias. Leukemia, 2009, 23, 1490-1499.	7.2	363
94	Determining the Repertoire of IGH Gene Rearrangements to Develop Molecular Markers for Minimal Residual Disease in B-Lineage Acute Lymphoblastic Leukemia. Journal of Molecular Diagnostics, 2009, 11, 194-200.	2.8	11
95	Sensitive and Specific Measurement of Minimal Residual Disease in Acute Lymphoblastic Leukemia. Journal of Molecular Diagnostics, 2009, 11, 201-210.	2.8	18
96	Improving minimal residual disease detection in precursor B-ALL based on immunoglobulin-Îº and heavy-chain gene rearrangements. Leukemia, 2008, 22, 2265-2267.	7.2	12
97	Minimal residual disease-directed risk stratification using real-time quantitative PCR analysis of immunoglobulin and T-cell receptor gene rearrangements in the international multicenter trial AIEOP-BFM ALL 2000 for childhood acute lymphoblastic leukemia. Leukemia, 2008, 22, 771-782.	7.2	339
98	Two cases of hypereosinophilia and high-risk acute lymphoblastic leukemia. Leukemia, 2008, 22, 1463-1465.	7.2	15
99	Mechanism of relapse in pediatric acute lymphoblastic leukemia. Cell Cycle, 2008, 7, 1315-1320.	2.6	25
100	<i>ODC1</i> Is a Critical Determinant of <i>MYCN</i> Oncogenesis and a Therapeutic Target in Neuroblastoma. Cancer Research, 2008, 68, 9735-9745.	0.9	200
101	Relapse in children with acute lymphoblastic leukemia involving selection of a preexisting drug-resistant subclone. Blood, 2007, 110, 632-639.	1.4	101
102	Optimization of PCR-based minimal residual disease diagnostics for childhood acute lymphoblastic leukemia in a multi-center setting. Leukemia, 2007, 21, 706-713.	7.2	139
103	Analysis of minimal residual disease by Ig/TCR gene rearrangements: guidelines for interpretation of real-time quantitative PCR data. Leukemia, 2007, 21, 604-611.	7.2	626
104	252A ORAL Relapse in children with acute lymphoblastic leukaemia is associated with selection of a pre-existing drug resistance subclone. European Journal of Cancer, Supplement, 2006, 4, 81.	2.2	0
105	PCR for monoclonal gene rearrangements can differentiate infantile acute lymphoblastic leukemia from cytomegalovirus infection. Leukemia Research, 2005, 29, 111-112.	0.8	0
106	Tyr-TGFÎ± transgenic mice develop ocular melanocytic lesions. Melanoma Research, 2002, 12, 435-439.	1.2	7
107	Endometrial expression of mRNA encoding insulin-like growth factors I and II and IGF-binding proteins 1 and 2 in early pregnant ewes. Reproduction, 1997, 111, 7-13.	2.6	16
108	Growth factor expression in skin during wool follicle development. Comparative Biochemistry and Physiology - B Biochemistry and Molecular Biology, 1995, 110, 697-705.	1.6	8

#	Article	IF	Citations
109	<i>MYC</i> Protooncogenes of Wool and Hair Growth^a. Annals of the New York Academy of Sciences, 1991, 642, 326-338.	3.8	13
110	Ovarian response to PMSG and GnRH in ewes immunised against oestradiol-17 beta. Veterinary Record, 1987, 120, 590-592.	0.3	10
111	Polyploid cells in blastocysts and early fetuses from Australian Merino sheep. Reproduction, 1986, 78, 439-446.	2.6	38
112	Oestrogen and seasonal effects on the production of an oestrus-associated glycoprotein in oviducal fluid of sheep. Reproduction, 1986, 77, 645-653.	2.6	32
113	Characterisation of a glycoprotein in oviductal fluid by two-dimensional electrophoresis and lectin binding to protein gel blots. Electrophoresis, 1985, 6, 516-520.	2.4	13
114	Embryonic chromosomal abnormalities and reproductive wastage in Fecundin treated and control Merino ewes. Theriogenology, 1985, 23, 211.	2.1	3
115	Ovarian Response to PMSG Treatment in Ewes Immunized against Oestradiol-17ÃŸ. Australian Journal of Biological Sciences, 1985, 38, 339.	0.5	8
116	Identification of an oestrus-associated glycoprotein in oviducal fluid of the sheep. Reproduction, 1984, 72, 415-422.	2.6	118
117	The diversity of allergens involved in bakers' asthma. Clinical and Experimental Allergy, 1984, 14, 93-107.	2.9	87
118	Towards gene transfer into ruminant embryos: Factors affecting the supply of embryos. Theriogenology, 1984, 21, 222.	2.1	2
119	Towards gene transfer into ruminant embryos: Effect of centrifugation. Theriogenology, 1984, 21, 248.	2.1	8
120	Antigens and allergens from the common house dust mite Dermatophagoides pteronyssinus. Journal of Allergy and Clinical Immunology, 1984, 74, 132-141.	2.9	47
121	Allergen discs prepared from nitrocellulose: Detection of IgE binding to soluble and insoluble allergens. Journal of Immunological Methods, 1984, 73, 139-145.	1.4	36
122	Detection of IgE- and IgG-binding proteins after electrophoretic transfer from polyacrylamide gels. Journal of Immunological Methods, 1982, 52, 183-194.	1.4	99
123	The Import of Carbamoyl-Phosphate Synthase into Mitochondria from Foetal Rat Liver. FEBS Journal, 1982, 125, 401-406.	0.2	9
124	Immunoglobulin E antibodies to ingested cereal flour components: studies with sera from subjects with asthma and eczema. Clinical and Experimental Allergy, 1982, 12, 63-74.	2.9	51
125	Carbohydrate Metabolism of Cactus in a Desert Environment. Plant Physiology, 1981, 68, 784-787.	4.8	40
126	Hormone-initiated maturation of rat liver mitochondria after birth. Biochemical Journal, 1980, 186, 361-367.	3.7	33

#	Article	IF	Citations
127	The transport and accumulation of adenine nucleotides during mitochondrial biogenesis. Biochemical Journal, 1980, 192, 75-83.	3.7	34
128	The differentiation of animal mitochondria during development. Trends in Biochemical Sciences, 1980, 5, 23-27.	7.5	43
129	The Increasing Adenine Nucleotide Concentration and the Maturation of Rat Liver Mitochondria during Neonatal Development. Differentiation, 1979, 12, 15-21.	1.9	56
130	The adenine nucleotide translocator in foetal, suckling and adult rat liver mitochondria. Biochemical and Biophysical Research Communications, 1978, 80, 193-198.	2.1	12
131	Evidence for repair of ozone induced membrane injury: Alteration in sugar uptake. Atmospheric Environment, 1977, 11, 273-275.	1.0	10
132	Evidence for the Repair of Ozone-Induced Membrane Injury. American Journal of Botany, 1977, 64, 404.	1.7	15